New resource available view now
New resource available view now
Recent Post
Related Posts
POTOMAC, Maryland – April 14, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”) today announced that it has approximately 80% patient enrollment in its Phase 2 CALMA clinical trial
POTOMAC, MARYLAND – April 08, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage biotechnology company with its lead program currently in a Phase 2 CALMA clinical trial evaluating IGC-AD1 for Alzheimer’s-related agitation today announced that Ascendiant Capital Markets has
IGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer’s Disease.
POTOMAC, MARYLAND – April 07, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage biotechnology company developing innovative treatments for Alzheimer’s disease, today announced the activation of a new clinical trial site
POTOMAC, MARYLAND – March 30, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage biotechnology company developing therapeutics for Alzheimer’s disease, today announced a strategic 12-part national media partnership with
IGC Pharma Reports Financial Results and Clinical Progress for the Period Ended December 31, 2025
Strategic Pivot to Pure-Play Biotech